Individual Article: A Novel 3-Step Over-the-Counter Eczema Regimen Improves Eczema Severity, Itch, and Life Quality: Randomized Study

October 2023 | Volume 22 | Issue 10 | SF388641s21 | Copyright © October 2023


Published online September 30, 2023

Kristi Hawley DO FAADa, Peter Lio MDb, Thu Nguyen PhDc, Aamir Qureshi MDc, Christine Emesiani PharmDc, Matthew Meckfessel PhDc

aThe Derm Institute of West Michigan; Michigan State University College of Osteopathic Medicine, Petoskey, MI 
bMedical Dermatology Associates of Chicago, Chicago, IL 
cGalderma Laboratories, L.P., Dallas, TX

common in African American, Asian, Hispanic, and Pacific Islander patients.2 Croce et al report that the burden of eczema is higher in these populations, with African American children having an almost double rate of eczema diagnoses compared to White children.2 African American and Latinx children are prone to more severe eczema and more likely to have persistent eczema.2 In turn, more severe and persistent eczema is linked to worse overall health.2,18-20 For these reasons, it is important for healthcare professionals to be aware that the clinical presentation of eczema is often different in light- vs dark-skinned individuals; light-skinned participants tend to have erythema and rash, while darker-skinned participants are more likely to exhibit primarily a purple discoloration and/or an ashy look to the skin.2

The results of this study demonstrate that this eczema skincare regimen is safe and effective for all skin types and for both children and adults (note that it has not been studied in infants).

DISCLOSURES

Dr. Kristi Hawley served as a PI for this trial; she reports receiving research grants from Lily, Sanofi, and Leo in the AD field; serves as a consultant and/or speaker for Arcutis, BMS, Dermavant, Incyte, Galderma, Sun Pharma, Amgen, Sanofi, Regeneron, Leo, Novartis, Janssen, Abbvie and UCB pharmaceuticals. Dr. Lio reports research grants/funding from AbbVie, AOBiome, National Eczema Association; is on the speaker's bureau for AbbVie, Arcutis, Eli Lilly, Galderma, Hyphens Pharma, Incyte, La Roche-Posay/L'Oreal, MyOR Diagnostics, ParentMD, Pfizer, Pierre-Fabre Dermatologie, Regeneron/Sanofi Genzyme, Verrica; reports consulting/advisory boards for Alphyn, AbbVie, Almirall, Amyris, Arcutis, ASLAN, Boston Skin Science, Bristol-Myers Squibb, Burt's Bees, Castle Biosciences, Codex Labs, Concerto Biosci, Dermavant, Eli Lilly, Galderma, Janssen, Johnson & Johnson, Kimberly-Clark, LEO Pharma, Lipidor, L'Oreal, Merck, Micreos, MyOR Diagnostics, Regeneron/Sanofi Genzyme, Skinfix, Theraplex, UCB, Unilever, Verrica Yobee Care; stock options with Codex, Concerto Biosciences and Yobee Care. In addition, Dr. Lio has a patent pending for a Theraplex product with royalties paid and is a Board member and Scientific Advisory Committee Member of the National Eczema Association. Dr. Nguyen, Dr. Qureshi, Dr. Emesiani, and Dr. Meckfessel are employees of Galderma Laboratories, LP.

REFERENCES

  1. Abuabara K, Magyari A, McCulloch CE, et al. Prevalence of atopic eczema among patients seen in primary care: Data from the health improvement network. Ann Intern Med. 2019;170:354-6. 
  2. Croce EA, Levy ML, Adamson AS, et al. Reframing racial and ethnic disparities in atopic dermatitis in black and latinx populations. J Allergy Clin Immunol. 2021;148:1104-11.
  3. Tollefson MM, Bruckner AL, Section On D. Atopic dermatitis: Skin-directed management. Pediatrics. 2014;134:e1735-44.
  4. Moore K, David TJ, Murray CS, et al. Effect of childhood eczema and asthma on parental sleep and well-being: A prospective comparative study. Br J Dermatol. 2006;154:514-8. 
  5. Achten R, Van der Rijst L, Piena M, et al. Economic and humanistic burden in paediatric patients with atopic dermatitis. Acta Derm Venereol. 2023;103:adv00881.
  6. Wang J, Zhou Y, Zhang H, et al. Pathogenesis of allergic diseases and implications for therapeutic interventions. Signal Transduct Target Ther. 2023;8:138.
  7. O'Regan GM, Irvine AD. The role of filaggrin in the atopic diathesis. Clin Exp Allergy. 2010;40:965-72.
  8. Drislane C , Irvine AD. The role of filaggrin in atopic dermatitis and allergic disease. Ann Allergy Asthma Immunol. 2020;124:36-43.
  9. Cork MJ, Britton J, Butler L, et al. Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse. Br J Dermatol. 2003;149:582-9.
  10. Short RW, Chan JL, Choi JM, et al. Effects of moisturization on epidermal homeostasis and differentiation. Clin Exp Dermatol. 2007;32:88-90.
  11. Loden M, Andersson AC, Lindberg M. Improvement in skin barrier function in patients with atopic dermatitis after treatment with a moisturizing cream (canoderm). Br J Dermatol. 1999;140:264-7.
  12. Miller DW, Koch SB, Yentzer BA, et al. An over-the-counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: A randomized, controlled trial. J Drugs Dermatol. 2011;10:531-7.
  13. Moret L, Anthoine E, Aubert-Wastiaux H, et al. Topicop(c): A new scale evaluating topical corticosteroid phobia among atopic dermatitis outpatients and their parents. PLoS One. 2013;8:e76493.
  14. Kojima R, Fujiwara T, Matsuda A, et al. Factors associated with steroid phobia in caregivers of children with atopic dermatitis. Pediatr Dermatol. 2013;30:29-35.
  15. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38:441-6.
  16. Jones VA, Patel PM, Wilson C, et al. Complementary and alternative medicine treatments for common skin diseases: A systematic review and meta-analysis. JAAD Int. 2021;2:76-93.
  17. Larese Filon F, Maculan P, Crivellaro MA, et al. Effectiveness of a skin care program with a cream containing ceramide c and a personalized training for secondary prevention of hand contact dermatitis. Dermatitis. 2023;34:127-34.
  18. Kim Y, Blomberg M, Rifas-Shiman SL, et al. Racial/ethnic differences in incidence and persistence of childhood atopic dermatitis. J Invest Dermatol. 2019;139:827-34.
  19. Silverberg JI , Simpson EL. Associations of childhood eczema severity: A us population-based study. Dermatitis. 2014;25:107-14.
  20. Leung DYM. The effect of being african american on atopic dermatitis. Ann Allergy Asthma Immunol. 2019;122:1.

AUTHOR CORRESPONDENCE

Christine Emesiani PharmD Christine.Emesiani@galderma.com
Close Menu